Finasteride Side Effects: Real Rates From Trials
What side effects does finasteride cause and how common are they?
Most men who take the 1 mg hair loss dose report nothing at all, which is exactly why the numbers matter more than the stories you'll find online. You're weighing a small, mostly early and mostly reversible chance of sexual side effects against a drug that quietly changes one blood test your doctor may rely on years from now. Get both halves of that picture and you can make the call yourself instead of guessing.
In the two-year trials of the 1 mg hair loss dose, drug-related sexual side effects were reported by about 3.8 percent of men against 2.1 percent on placebo, and roughly 1.2 percent stopped treatment because of them.
Which sexual side effects are reported with finasteride and how often do controlled trials find them?
Three complaints cover nearly everything reported here: your libido drops, erections get harder to get or keep, or you notice less fluid when you ejaculate. What the trial data shows is that the drug's own share of those complaints is small, because a real slice of the same reports came from men swallowing a dummy tablet. Read the two columns side by side and the actual size of the risk stops being a rumour.
| First-year rate | Finasteride 1 mg (945 men) | Placebo (934 men) |
|---|---|---|
| Decreased libido | about 1.8% | about 1.3% |
| Erectile difficulty | about 1.3% | about 0.7% |
| Reduced ejaculate volume | under 1% | about 0.4% |
| Any drug-related sexual event | about 3.8% | about 2.1% |
| Left the trial because of it | about 1.2% | about 0.9% |
Across 945 men on 1 mg and 934 on placebo, first-year rates ran near 1.8 percent versus 1.3 percent for decreased libido, 1.3 percent versus 0.7 percent for erectile difficulty, and under 1 percent versus 0.4 percent for reduced ejaculate volume.
How often do side effects persist after stopping finasteride, and what is actually known about post-finasteride syndrome?
This is the one question where the honest answer is that nobody knows the rate. Some former users describe libido loss, erectile difficulty, blunted genital sensation, low mood and mental fog that didn't lift after the last tablet, and regulators put that on the label rather than waving it off. What you won't get from anyone, including the people selling you the drug and the people warning you off it, is a number.
- Label acknowledgement: US labeling records libido, ejaculation and orgasm disorders continuing after men stop.
- Evidence base: Case series and self-selected online cohorts, which by design can't produce a rate.
- Database attempts: Mixed and contested findings once confounders are handled properly.
- Proposed mechanisms: Neurosteroid and androgen receptor changes, both plausible, neither demonstrated.
United States labeling was revised in 2012 to record post-marketing reports of libido disorders, ejaculation disorders and orgasm disorders continuing after discontinuation, but neither the frequency nor the cause of that persistent state has been established.
What does the evidence show about finasteride, depression, anxiety and cognitive complaints?
Mood is the newest item on the list and the one where the warnings have run out ahead of the proof. Stack the evidence by how much weight it can actually carry and you'll see why nobody can tell you the risk is proven or that it's been ruled out.
Depression is listed among reported adverse reactions in most major markets on the strength of post-marketing reports, while randomized trials of both the 1 mg and 5 mg doses have shown no clear increase over placebo.
How does the 1 mg hair loss dose compare with the 5 mg prostate dose for side effect frequency?
You'd expect five times the dose to mean five times the trouble, and that's not how this drug works. The enzyme it blocks is nearly saturated at 1 mg, so the extra 4 mg buys only a few more points of hormone suppression. The reported rates still look very different, and most of that gap is who was in each trial rather than what was in the tablet.
| Measure | Finasteride 1 mg (hair loss) | Finasteride 5 mg (prostate) |
|---|---|---|
| Serum dihydrotestosterone drop | roughly 65% | roughly 70% |
| Impotence, first year | about 1.3% | about 8% |
| Decreased libido, first year | about 1.8% | about 6% |
| Reduced ejaculate volume | under 1% | about 4% |
| Trial population age | men with hair loss, younger | men aged 45 to 78 with urinary symptoms |
Finasteride 1 mg lowers serum dihydrotestosterone by roughly 65 percent and 5 mg lowers it by roughly 70 percent, so a fivefold difference in dose buys only about five percentage points more hormone suppression.
Why do placebo groups report similar symptoms, and how much does expectation shape the reported rates?
Here's what most men never see: about half the sexual side effects reported in the treated group would have happened without any active drug in the tablet. That isn't a reason to dismiss anyone's symptoms, because a symptom driven by worry is still genuinely experienced. It does mean how the risk gets explained to you measurably changes how often you'll feel it.
- The placebo column: 2.1 percent reported sexual side effects on a dummy tablet.
- The counselling study: 44 percent reported dysfunction when warned, 15 percent when not told.
- Background rate: Erectile difficulty is already common in men in their thirties and forties.
Among men prescribed 5 mg finasteride, those told the drug might cause sexual problems reported sexual dysfunction at roughly 44 percent after a year against roughly 15 percent of men who weren't told, on identical medication.
How does finasteride change PSA readings and what does that mean for prostate cancer screening?
This one isn't a side effect so much as a silently altered test result, and it may end up mattering more than anything on the adverse event list. The drug holds your PSA down for as long as you take it, so a reading that looks comfortably normal can be hiding a number that would have prompted a closer look. The trap is a records problem: you don't think of a hair tablet as a prostate drug, so you don't mention it.
- Put it on the medication list: Name finasteride to every new physician, and say it again whenever PSA is being ordered.
- Double the value: After six months or more of treatment, a PSA is conventionally doubled before it's compared against reference ranges.
- Watch the trend, not just the level: Because the drug suppresses PSA, any sustained rise during treatment deserves assessment even inside the normal range.
- Know when it starts to count: In your twenties and thirties this is theoretical; from around forty to fifty onward it's practical.
The 5 mg dose lowers serum PSA by roughly 50 percent within six months, and the 1 mg hair loss trials recorded a smaller mean fall from 0.7 to 0.5 ng/mL by month twelve.
Who should not take finasteride, and what handling precautions apply around pregnancy?
One line on this drug's label isn't a precautionary formality, and it isn't about you. Dihydrotestosterone builds the external genitalia of a male fetus, so a drug that shuts its production down can cause abnormal development if it reaches that fetus. Sort the rest by how hard the boundary is and the eligibility question gets simple.
Finasteride is contraindicated in women who are pregnant or may become pregnant because inhibiting 5-alpha reductase can interfere with development of male fetal genitalia, while drug measured in the semen of treated men sits orders of magnitude below the lowest dose shown to affect a fetus.
What monitoring, dose adjustment or discontinuation steps make sense if side effects appear?
Attribution is the hard part here, and your memory will rebuild the timeline wrong within weeks. A short, unglamorous record beats any amount of reading about other men's experiences, because it lets you and your clinician tell a drug effect from a bad month.
- Separate out what can't wait: A new breast lump, nipple discharge or skin change, swelling of the lips or face, rash with systemic symptoms, or any thought of self-harm means prompt medical contact, not observation.
- Write down a baseline first: A brief note on sexual function, mood and relevant blood work costs nothing before you start and can't be recovered later.
- Log the symptom against the calendar: What it is, when it began relative to your first dose, and how it behaves day to day.
- Give tolerance a few weeks to a few months: Long enough to see whether an early complaint settles, which many do, without gritting your teeth through a genuinely bad experience.
- Reduce exposure before you abandon it: Lower daily dose, alternate-day or twice-weekly dosing, or a topical formulation, none of which is proven to keep the hair while removing the effect.
If you stop finasteride, dihydrotestosterone levels recover quickly after the last dose while the hair benefit you were holding is lost over roughly six to twelve months as miniaturization resumes its previous course.
Does topical finasteride actually reduce systemic side effects compared with oral dosing?
Topical finasteride lowers how much drug gets into your blood; it doesn't get it to zero. That's the honest version of the pitch, and it still matters, because scalp tissue sees a comparable effect while your circulation sees a fraction of one. Where it gets thin is the long game, since the tolerability evidence runs to months rather than years.
| Measure | Topical 0.25% solution | Oral 1 mg tablet |
|---|---|---|
| Serum dihydrotestosterone drop | roughly 35 to 45% | roughly 65% |
| Scalp tissue dihydrotestosterone | falls comparably | reference |
| Systemic drug exposure | more than 100x lower | reference |
| Hair count versus placebo | significantly better | significantly better |
| Length of tolerability data | months | years |
A 0.25 percent topical finasteride solution suppresses serum dihydrotestosterone by roughly 35 to 45 percent against roughly 65 percent for a 1 mg tablet, so the honest claim is reduced systemic risk rather than none.
